[1]刘文君,王亿平,吕 伟,等.益气护肾方佐治慢性肾衰竭3～5期肾气虚夹瘀临床研究[J].陕西中医,2024,(8):1056-1060.[doi:DOI:10.3969/j.issn.1000-7369.2024.08.010]
　LIU Wenjun,WANG Yiping,LYU Wei,et al.Clinical efficacy of Yiqi Hushen decoction adjuvant therapy on patients with stage 3～5 chronic renal failure with syndrome of kidney deficiency and blood stasis[J].,2024,(8):1056-1060.[doi:DOI:10.3969/j.issn.1000-7369.2024.08.010]
点击复制

益气护肾方佐治慢性肾衰竭3～5期肾气虚夹瘀临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年8期
页码:
1056-1060
栏目:
临床研究
出版日期:
2024-08-05

文章信息/Info

Title:
Clinical efficacy of Yiqi Hushen decoction adjuvant therapy on patients with stage 3～5 chronic renal failure with syndrome of kidney deficiency and blood stasis
作者:
刘文君1; 王亿平2; 吕 伟1; 刘诗富1
(1.芜湖市中医医院肾病科,安徽 芜湖 241001; 2.安徽中医药大学第一附属医院 安徽省中医院肾内科,安徽 合肥 230031)
Author(s):
LIU Wenjun; WANG Yiping; LYU Wei; LIU Shifu
(Department of Nephrology,Wuhu Hospital of Traditional Chinese Medicine,Wuhu 241001,China)
关键词:
慢性肾衰竭;  肾气虚夹瘀;  中医症状积分;  肾功能;  氧化应激;  炎性因子
Keywords:
Chronic renal failure;  Kidney deficiency and blood stasis;  TCM symptoms scores;  Renal function;  Oxidative stress;  Inflammatory factors
分类号:
R 692.5
DOI:
DOI:10.3969/j.issn.1000-7369.2024.08.010
文献标志码:
A
摘要:
目的:观察益气护肾方佐治慢性肾衰竭(CRF)3～5期肾气虚夹瘀患者的临床疗效。方法:选取106例肾气虚夹瘀CRF 3～5期患者作为研究对象,按照随机数字表法分为常规组(予以常规治疗及穴位贴敷和中药直肠滴入治疗)和益气护肾组(在常规组基础上联合使用益气护肾方治疗),每组53例。比较两组临床疗效、中医症状积分、治疗前后肾功能[肾小球滤过率(eGFR)、血肌酐(Scr)、尿素氮(BUN)、24 h尿蛋白定量(24 h-UPRO)]、炎性因子[粒细胞-巨噬细胞集落刺激因子(GM-CSF)、白细胞诱素-1(LKN-1)、肿瘤坏死因子-α(TNF-α)]、氧化应激指标[晚期糖基化终产物(AGEs)、丙二醛(MDA)、活性氧(ROS)]。结果:益气护肾组总有效率高于常规组(P<0.05)。治疗后,两组中医症状评分下降,且益气护肾组低于常规组(均P<0.05)。治疗后,两组Scr、BUN、24 h-UPRO下降,eGFR升高(均P<0.05),且组间比较差异具有统计学意义(均P<0.05)。治疗后,两组GM-CSF、LKN-1、TNF-α水平下降,且益气护肾组低于常规组(均P<0.05)。治疗后,两组AGEs、MDA、ROS水平下降,且益气护肾组低于常规组(均P<0.05)。结论:益气护肾方佐治CRF 3～5期肾气虚夹瘀患者可调节其炎症因子水平,减轻氧化应激反应和肾损伤,从而改善患者症状和提高疗效。
Abstract:
Objective:To observe the clinical efficacy of Yiqi Hushen decoction in the adjuvant treatment of patients with stage 3～5 chronic renal failure(CRF)with syndrome of kidney deficiency and blood stasis.Methods:106 patients with stage 3～5 CRF with syndrome of kidney deficiency and blood stasis were selected as the research subjects.According to the random number table method,they were divided into conventional group(conventional treatment,acupoint application and rectal drip of traditional Chinese medicine)and Yiqi Hushen group(Yiqi Hushen decoction on the basis of conventional group),with 53 cases in each group.The two groups were compared in terms of clinical efficacy,TCM symptoms scores,renal function [estimated glomerular filtration rate(eGFR),serum creatinine(Scr),blood urea nitrogen(BUN),24-hour urinary protein quantification(24 h-UPRO)],inflammatory factors [granulocyte-macrophage colony-stimulating factor(GM-CSF),leukotactin-1(LKN-1),tumor necrosis factor-α(TNF-α)] and oxidative stress indicators [advanced glycation end products(AGEs),malondialdehyde(MDA),reactive oxygen species(ROS)] before and after treatment.Results:The total effective rate in Yiqi Hushen group was higher compared to conventional group(P<0.05).The scores of TCM syndromes were declined in groups after treatment,and the scores in Yiqi Hushen group were lower than those in conventional group(all P<0.05).The levels of Scr,BUN and 24 h-UPRO were reduced in both groups after treatment,while the level of eGFR was enhanced(all P<0.05),and there were statistical differences between groups after treatment(all P<0.05).The levels of GM-CSF,LKN-1 and TNF-α were declined in both groups after treatment,and the levels after treatment were lower in Yiqi Hushen group than those in conventional group(all P<0.05).After treatment,the levels of AGEs,MDA and ROS in the two groups were lowered,and the Yiqi Hushen group had lower AGEs,MDA and ROS(all P<0.05).Conclusion:Yiqi Hushen decoction can regulate the levels of inflammatory factors,relieve the oxidative stress response and renal injury,improve the symptoms and enhance the efficacy in the adjuvant treatment of patients with stage 3～5 CRF with syndrome of kidney deficiency and blood stasis.

参考文献/References:

[1] 邓跃毅.慢性肾脏病中西医结合诊疗难点及展望[J].中国中西医结合杂志,2019,39(7):776-777.
[2] 张志勇,李明旭,于海,等.自动化腹膜透析对终末期肾衰竭患者心功能和临床症状的影响[J].陕西医学杂志,2020,49(9):1130-1133.
[3] 赵静,何伟明,高坤,等.慢性肾脏病“肾虚湿瘀”核心病机理论渊源[J].世界科学技术-中医药现代化,2019,21(6):1085-1088.
[4] 孙蓓蓓,王云满,毕月萍,等.中医辨证治疗206例慢性肾脏病1-2期多中心前瞻性临床研究[J].中华中医药杂志,2019,34(11):5479-5483.
[5] 严梦婷,林钐,王江梅,等.高位结肠透析联合中药保留灌肠治疗慢性肾脏病4-5期湿浊证的临床观察[J].时珍国医国药,2022,33(9):2198-2220.
[6] 王艳芬,马琴,王顺.肾康注射液联合穴位敷贴治疗慢性肾功能衰竭疗效及作用机制[J].陕西中医,2023,44(5):595-599.
[7] 上海慢性肾脏病早发现及规范化诊治与示范项目专家组.慢性肾脏病筛查诊断及防治指南[J].中国实用内科杂志,2017,37(1):28-34.
[8] 国家食品药品监督管理局.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:163.
[9] 王禹霖,刘梦超,郑冰洁,等.名中医张炳厚从瘀论治慢性肾脏病经验撷英[J].陕西中医,2023,44(11):1602-1605.
[10] 石翎笙,贺娟.《黄帝内经》“正气”概念内涵辨析[J].北京中医药大学学报,2020,43(6):469-474.
[11] 廖林丽,李翔,邓颖,等.慢性肾脏病107例患者中医证素分布特点[J].中华中医药杂志,2022,37(11):6682-6686.
[12] 闫蕾,郎睿,王殿文,等.从痰瘀论治慢性肾脏病理论源流述略[J].中华中医药杂志,2022,37(9):5155-5158.
[13] 谢晨,陆红梅,夏松辰,等.李建民辨治慢性肾脏病浮阳的经验分析[J].中华中医药杂志,2018,33(5):1971-1974.
[14] 费佳,马源,陈玉,等.活血益肾方治疗慢性肾脏病2-4期血瘀证的疗效观察[J].时珍国医国药,2020,31(5):1174-1176.
[15] 李青,严谨,孙伟.益肾清利活血泄浊方延缓慢性肾脏病进展回顾性研究[J].中国中西医结合杂志,2019,39(7):787-790.
[16] 姚律,黄小抗,朱琼.慢性肾衰竭患者并发心血管疾病相关危险因素分析[J].陕西医学杂志,2024,53(1):55-58,63.
[17] 康婷,陈波,欧三桃.慢性肾脏病血管钙化大鼠血清炎症因子抗体芯片检测及分析[J].中国比较医学杂志,2019,29(1):9-15.
[18] 王敏,张立元,马国平,等.参乌益肾片对慢性肾脏病4-5期肾间质纤维化和微炎症状态的影响观察[J].中国实验方剂学杂志,2020,26(23):125-130.
[19] 罗肖肖,张畅,赵蕾,等.炎症反应通过上调CD36表达促进小鼠肾脏损伤[J].中国病理生理杂志,2019,35(1):174-180.
[20] JAGANJAC M,MILKOVIC L,ZARKOVIC N,et al.Oxidative stress and regeneration[J].Free Radic Biol Med,2022,181:154-165.
[21] DUNI A,LIAKOPOULOS V,ROUMELIOTIS S,et al.Oxidative stress in the pathogenesis and evolution of chronic kidney disease:Untangling ariadne's thread[J].Int J Mol Sci,2019,20(15):3711.
[22] HO H J,SHIRAKAWA H.Oxidative stress and mitochondrial dysfunction in chronic kidney disease[J].Cells,2022,12(1):88.
[23] WANG Y,YANG J,ZHANG Y,et al.Focus on mitochondrial respiratory chain:Potential therapeutic target for chronic renal failure[J].Int J Mol Sci,2024,25(2):949.
[24] RABBANI N,THORNALLEY P J.Advanced glycation end products in the pathogenesis of chronic kidney disease[J].Kidney Int,2018,93(4):803-813.
[25] SHEKHAR R,SAGAR P,PRANAY K,et al.Serum malondialdehyde in different stages of chronic renal disorder[J].Asian Journal of Medical Sciences,2023,14(6):113-118.

相似文献/References:

[1]郑 栓,万红波,郑建国,等.健脾补肾活血泄浊方联合杂合式血液净化疗法对慢性肾衰竭患者 肾功能及血清CD4+/CD8+水平的影响*[J].陕西中医,2019,(2):188.
　ZHENG Shuan,WAN Hongbo,ZHENG Jianguo,et al.Effect of Jianpi Bushen Huoxue Xiezhuo decoction combined with hybrid blood purification therapy on renal function and serum CD4+/CD8+ levels in patients with chronic renal failure[J].,2019,(8):188.
[2]张春艳,李 浩,李 娜,等.肾浊清颗粒含药血清对肾小管上皮细胞TGFβ/Smads信号传导的影响*[J].陕西中医,2019,(10):1323.
　ZHANG Chunyan,LI Hao,LI Na,et al.Effect of Shenzhuoqing granulecontaining serum on TGFβ/Smads signal transduction in renal tubular epithelial cells[J].,2019,(8):1323.
[3]王世卫,韩 佳,马民凯△,等.健脾补肾活血化瘀法治疗慢性肾功能衰竭疗效及对患者肾功能的影响*[J].陕西中医,2020,(11):1598.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.022]
[4]陈小燕,杨敏生,曹 雯.肾衰复元汤治疗慢性肾衰竭疗效观察[J].陕西中医,2021,(10):1397.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.018]
[5]李慧灵,张建德,叶 静,等.加味玉液汤治疗气阴两虚型糖尿病肾病慢性肾衰竭疗效及对患者微炎症状态的影响[J].陕西中医,2022,(8):1064.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.018]
[6]王艳芬,马 琴,王 顺.肾康注射液联合穴位敷贴治疗慢性肾功能衰竭疗效及作用机制[J].陕西中医,2023,(5):595.[doi:DOI:10.3969/j.issn.1000-7369.2023.05.012]
　WANG Yanfen,MA Qin,WANG Shun.Effects and mechanism of action of Shenkang injection combined with acupoint application on chronic renal failure[J].,2023,(8):595.[doi:DOI:10.3969/j.issn.1000-7369.2023.05.012]
[7]郭传琦,艾 健.温肾泄浊汤治疗慢性肾衰竭73例疗效研究[J].陕西中医,2023,(9):1237.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.018]
　GUO Chuanqi,AI Jian.Effect of Wenshen Xiezhuo decoction on chronic renal failure[J].,2023,(8):1237.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.018]
[8]罗玉芳,李怀玉,吕森浩,等.肾衰泄浊汤对腺嘌呤致肾阳虚型慢性肾衰竭大鼠下丘脑-垂体-肾上腺轴的影响[J].陕西中医,2024,(9):1161.[doi:DOI:10.3969/j.issn.1000-7369.2024.09.002]
　LUO Yufang,LI Huaiyu,LYU Senhao,et al.Effects of Shenshuai Xiezhuo decoction on HPA axis in rats with chronic renal failure of kidney-yang deficiency caused by adenine[J].,2024,(8):1161.[doi:DOI:10.3969/j.issn.1000-7369.2024.09.002]

备注/Memo

备注/Memo:
基金项目:安徽省重点研究与开发计划项目(202104J07020014)
更新日期/Last Update: 2024-08-08